-
Tarceva
-
Scientific Information
- Erlotinib clinical trials
- Erlotinib plus bevacizumab combination studies
-
Erlotinib real-world evidence and retrospective analyses
- Real-world evidence: Flatiron Electronic Health Record Database study of EGFR TKIs
- Retrospective analysis: erlotinib vs gefitinib in Asian patients with newly diagnosed brain metastases
- Retrospective analysis: clinical outcomes in patients treated with EGFR TKIs in Taiwan
- Comparative study: CNS progression in response to treatment with gefitinib or erlotinib
- Retrospective analysis: T790M occurrence rate in patients treated with EGFR TKIs
-
Scientific Information
-
Scientific Information
- Erlotinib clinical trials
- Erlotinib plus bevacizumab combination studies
-
Erlotinib real-world evidence and retrospective analyses
- Real-world evidence: Flatiron Electronic Health Record Database study of EGFR TKIs
- Retrospective analysis: erlotinib vs gefitinib in Asian patients with newly diagnosed brain metastases
- Retrospective analysis: clinical outcomes in patients treated with EGFR TKIs in Taiwan
- Comparative study: CNS progression in response to treatment with gefitinib or erlotinib
- Retrospective analysis: T790M occurrence rate in patients treated with EGFR TKIs
- Erlotinib plus bevacizumab combination studies
- ARTEMIS (CTONG 1509) investigator interview video
ARTEMIS (CTONG 1509) Principle Investigator Interview Video
First phase III trial of bevacizumab +/- erlotinib in Chinese patients with 1L EGFR Mut+ NSCLC (CTONG 1509)
Please note; in some countries the combination of erlotinib plus bevacizumab may not be registered or reimbursed